Effect of CoQ10 Plus Selenium Supplementation on Clinical Outcomes &

Status Completed

Clinical Trial Summary

In recent years, it has been suggested that nutritional deficiencies may be of causal relevance in individuals with ME/CFS. These include deficiencies of vitamins and trace elements. It is likely that the observed nutritional deficiencies contribute to the core symptoms of the disease. Coenzyme Q10 (CoQ10) has been studied as an alternative and complementary therapy in ME/CFS for fatigue, pain, tiredness, neurocognitive impairment, and sleep problems. This demonstrates how alterations in energy metabolism, mitochondrial dysfunction, oxidative stress, imbalance of the immune-inflammatory response, and activation of the NLRP3 inflammasome are likely consequences of low levels of CoQ10 and selenium, which are related to the main symptoms in ME/CFS. Hypothesis: CoQ10 and selenium levels are decreased in ME/CFS patients. A natural therapeutic alternative in the treatment of common symptoms in ME/CFS could be the oral CoQ10 (Ubiquinone) plus selenium supplementation to module redox status and inflammation response in ME/CFS. Aims: To evaluate the efficacy of oral Ubiquinone + selenium supplementation on clinical outcome and circulating biomarkers in ME/CFS. We enrolled 42 ME/CFS patients diagnosed according to the 1994 CDC/Fukuda criteria who have received oral treatment of 400 mg Ubiquinone + 200 microgram selenium daily for 8 weeks. Demographic, clinical characteristics and laboratory variables, and validated outcome measures to perceived fatigue, sleep disturbances, and quality of life will be also evaluated. In addition, plasma biomarkers related to oxidative stress status (total antioxidant capacity and lipoperoxide levels), inflammatory response (pro-and anti-inflammatory cytokines), and cardiovascular dysfunction (FGF-21 and NT-proBNP) will be assayed.

Clinical Trial Description

n/a

Study Design

Related Conditions & MeSH terms

Clinical Trial Details

NCT number	NCT05128292
Study type	Interventional
Source	Hospital Universitari Vall d'Hebron Research Institute
Contact
Status	Completed
Phase	N/A
Start date	January 1, 2018
Completion date	November 30, 2018

View Details

See also
Status	Clinical Trial	Phase
Recruiting	`NCT05454683` - Melatonin and Zinc Administration on Cardinal Symptoms in Myalgic Encephalomyelitis/Chronic Fatigue Syndrome	N/A
Recruiting	`NCT05059184` - Long-term Sequelae of COVID-19 (Myalgic Encephalomyelitis): An International Cross-Sectional Study
Recruiting	`NCT04542161` - Assessment of N-Acetylcysteine as Therapy for Myalgic Encephalomyelitis/Chronic Fatigue Syndrome	Phase 2
Terminated	`NCT01730495` - Tumor Necrosis Factor-alpha Inhibition Using Etanercept in Chronic Fatigue Syndrome	Phase 2
Completed	`NCT01156909` - B-cell Depletion Using the Monoclonal Anti-CD20 Antibody Rituximab in Chronic Fatigue Syndrome	Phase 2
Active, not recruiting	`NCT05167227` - Does a Technology Enabled Multi-disciplinary Team-based Care Model for the Management of Long COVID and Other Fatiguing Illnesses Improve Clinical Care of Patients and Represent a Sustainable Approach Within a Federally Qualified Health Center?	N/A
Recruiting	`NCT05741112` - The Long COVID-19 Wearable Device Study	N/A
Completed	`NCT04301609` - Clinical Trial to Assess the Improvement of Fatigue, Sleep Problems, Anxiety / Depression, Neurovegetatives Alterations and Quality of Life After the Administration of ImmunoVita® in Chronic Fatigue Syndrome Patients	N/A
Completed	`NCT05196529` - Inspiratory Muscle Training in ME/CFS and COVID-19 Survivors	N/A
Completed	`NCT00920777` - Survey and Cognitive Behavior Therapy for Chronic Fatigue Syndrome/Myalgic Encephalomyelitis	N/A
Completed	`NCT04741841` - Effect of Probiotics in Myalgic Encephalomyelitis/Chronic Fatigue Syndrome (ME/CFS)	N/A
Enrolling by invitation	`NCT03254823` - Autoimmunity in Myalgic Encephalomyelitis/Chronic Fatigue Syndrome (ME/CFS)
Recruiting	`NCT05236465` - A 3-day Course for CFS/ME	N/A
Recruiting	`NCT04100915` - A Non-Interventional Pilot Study to Explore the Role of Gut Flora in ME/CFS
Active, not recruiting	`NCT05664711` - Effect of Stellate Ganglion Block on ME/CFS	Phase 1
Enrolling by invitation	`NCT05273372` - RESTORE ME -- RCT of Oxaloacetate on Improving Fatigue in ME/CFS	N/A
Completed	`NCT02970240` - Cardiopulmonary Testing in ME/CFS to Improve Diagnostic Accuracy
Terminated	`NCT01156922` - B-cell Depletion Using the Monoclonal Anti-CD20 Antibody Rituximab in Very Severe Chronic Fatigue Syndrome	Phase 2
Enrolling by invitation	`NCT03409653` - Complex Chronic Diseases Program Data Registry
Completed	`NCT03613129` - Clinical Trial to Investigate CT38 in the Treatment of Myalgic Encephalomyelitis / Chronic Fatigue Syndrome	Phase 1/Phase 2

Clinical trials are conducted in a series of steps, called phases - each phase is designed to answer a separate research question.

Phase 1: Researchers test a new drug or treatment in a small group of people for the first time to evaluate its safety, determine a safe dosage range, and identify side effects.
Phase 2: The drug or treatment is given to a larger group of people to see if it is effective and to further evaluate its safety.
Phase 3: The drug or treatment is given to large groups of people to confirm its effectiveness, monitor side effects, compare it to commonly used treatments, and collect information that will allow the drug or treatment to be used safely.
Phase 4: Studies are done after the drug or treatment has been marketed to gather information on the drug's effect in various populations and any side effects associated with long-term use.

Effect of CoQ10 Plus Selenium Supplementation on Clinical Outcomes and Biochemical Markers in ME/CFS (CoSeME Study) — CoSeME

Clinical Trial Summary

Clinical Trial Description

Study Design

Related Conditions & MeSH terms